Group Members:

Md.Mushfiq Iqbal Hossain Shapar Newaz Tasvir A R Chowdhury

Largest exporters of medicine in Bangladesh A local company with a global vision

An emerging globally competitive industry

Beximco boasts world-class facilities Core Values of Beximco Pharmaceuticals

- some Key Facts

New product and service offerings & international recognition Research & Development: key to global competence Beximco - Staying ahead of the game

- some statistical data

Competitive Advantages and the ways it changes over time:

Distinguished operational capability

In 1980 it was small in operation but big in dreams and passionate with its vision building a healthier tomorrow where people will live longer, healthier and happier. Its activities have always been centered on developing core competencies to deliver the best in the industry ensuring superior value and return to customers.

 Consistently

delivering high quality

products
Today, the name Beximco Pharma has become synonymous with trust and reliability. Quality is its relentless passion. Quality is ingrained in our values and in all that it does. Beximco Pharmas business processes and practices are designed to achieve quality results that would meet the expectations of patients and physicians by getting the highest quality products, and of shareholders and stakeholders through achieving returns.

 Professional

Management Capability

Beximco Pharma is the pioneer in implementing corporate governance to professionally run a company in Bangladesh. Beximco Pharma provides an environment which fosters creativity, innovation, selfdevelopment and entrepreneurship.
Adopting

innovation in manufacturing process Beximco Pharma has always been the pioneer in adopting innovative technologies that introduced both sophistication and scale in our business processes. It also focuses on improving manufacturing efficiency to meet the challenge of maintaining the bottom line of the business in an ever-changing competitive market place.

 R&D

capability in both formulation and API (Active Pharmaceutical Ingredients) R&D is another area where Beximco Pharma has already shown capability and led the Bangladesh Pharmaceutical Market in both formulation R&D and API R&D. Its formulation R&D capability is proven not only by the consistent quality of its products but also by its ability to introduce hitech, specialized products and dosage forms. The reverse engineering capability of the R&D team has enabled it to introduce innovative new products to serve the ailing people at home and abroad.

Sales & Marketing capability focused on brand building

The major source of competitive advantages of Beximco Pharma is its sales and marketing team. Its marketing team is composed of innovative people from diverse discipline. Because of the innovative & creative approach adopted by its marketing team, it has been able to create many vibrant brands like Napa, Neoceptin-R, Amdocal, Neofloxin, Tycil, Omastin, Azmasol, Bexitrol-F, Atova, Bextram Gold etc. Infact, the ability of its sales & marketing team to differentiate our brands even in a crowded generic market is Beximco Pharmas major competitive advantage.

 Experience

in foreign markets

Beximco Pharma always took the leading, proactive and pioneering role in exporting pharmaceuticals from Bangladesh It is the pioneer in exporting APIs, IV Fluids and hi-tech specialized products. It is the first pharmaceutical company in Bangladesh to enter CIS countries. It is also pioneer to enter African markets. It is the only company in Bangladesh to supply medicines to Raffles Hospital and KK Women & Children Hospital of Singapore. It is the only company in Bangladesh to supply medicines to Raffles Hospital and KK Women & Children Hospital of Singapore.

Future growth potential Domestic and existing export markets Its past and present performances clearly suggest that it has ample scope to grow even in the domestic as well as in our existing export markets. Beximco Pharma has already identified some attractive niche markets where the investment is negligible as compared to its expected returns in terms of profitability. Once the new OSD (Oral Solide Dosage) plant is operational and it has the capacity, confidently, it will be able to capitalize on these opportunities and increase its market share in the domestic market as well as in other existing export markets.

New export markets Each year patents on pharmaceutical products expire with annual sales worth billions of dollars. Data monitor estimates that there are blockbuster drugs coming off-patent by 2007 which have sales in excess of US $82 billion. This will be one of the key factors which will help drive generic pharmaceutical growth over the next decade. Beximco Pharma is seeking for position to take advantage of this growing generic market by regularly introducing new products in its existing and new markets. Its low manufacturing cost will provide a competitive edge over our global competitors in any international generic pharmaceutical market.

 Contract

Manufacturing

Cost of medication is becoming a major concern even in the developed countries. This particular issue coupled with severe price competition from the generic manufacturers has prompted a number of giant multinational companies to shift or outsource their production from developed to developing and less developed countries, because of huge cost advantage. It is believed that the world pharmaceutical market will continue to see more consolidation than ever across the entire value chain of the pharmaceutical business. Big companies will continue to look for suitable partners in their supply chain management in order to reduce their cost of production.
Beximco Pharma has always operated like a multinational in terms of professionalism and infrastructure so as to build the platform to become a global player. Management has adhered to international regulatory standards which is more preferable to our international partners.

Sales Growth Rate

Growth Rates (%)
Sales Fixed Asset Operating Cost Current Asset Retained Earning Share Price Non-current Liability Current Liability EPS

2008
14.23217 11.23766 28.23258 10.95183 16.64884 24.30525 1.624435 12.70519 8.428821

2007
-2.84395 5.54667 -0.99797 -12.9153 3.786453 9.683426 44.54765 -35.5876 -25.0608

2006
11.28017 14.83951 18.03202 -3.96058 16.55193 -7.09343 -11.5582 1.023103 -35.3774

2005
38.47012 20.40813 78.44515 41.4457 41.04439 -37.2421 -23.4905 47.03386 35.03185

2004
10.02235 4.156333 17.45111 19.23751 5.212577 131.8731 -3.00112 38.35137 59.12162

STDEV
17.3734379 7.737429242 34.62185398 24.43050677 17.23738 74.29356 29.82361 37.88072 45.89124

Pro Forma Statements - Income

2007 1 2 3 4 5 Net Sales Revenue Cost of Goods Sold Gross Profit (2-1) Administrative Expenses Selling, Marketing and Distribution Expenses
(829,191,989) (947,186,009) (1,081,970,578) (1,235,934,991) (1,411,808,541) (1,612,708,896)

2008

2009

2010

2011

2112

3,597,024,812 (1,967,509,975) 1,629,514,837 (145,544,701)

4,108,881,443 (2,247,486,644) 1,861,394,798 (166,255,712)

4,693,575,272 (2,567,303,994) 2,126,271,278 (189,913,900)

5,361,471,033 (2,932,631,352) 2,428,839,681 (216,938,648)

6,124,408,361 (3,349,944,794) 2,774,463,568 (247,809,017)

6,995,911,671 (3,826,641,938) 3,169,269,733 (283,072,240)

6 7 8 9 10 11

Operating Expenses Profit from Operations Other Income Finance Cost Profit Before Contribution to WPPF Contribution Funds to Workers' Profit Participation/ Welfare

(974,736,690) 654,778,147 19,625,795 (254,742,392)

(1,113,441,721) 747,953,077 22,418,546 (290,992,234)

(1,271,884,478) 854,386,800 25,608,705 (332,400,429)

(1,452,873,639) 975,966,042 29,252,823 (379,701,010)

(1,659,617,558) 1,114,846,010 33,415,500 (433,732,464)

(1,895,781,136) 1,273,488,597 38,170,526 (495,452,594)

419,661,550

479,379,389

547,595,076

625,517,855

714,529,046

816,206,529

(19,983,883)

(22,827,590)

(26,075,956)

(29,786,564)

(34,025,192)

(38,866,977)

12 13 14 15 16

Profit Before Tax Current Tax Deferred Tax Income/(Expense) Income Tax Expense Profit After Tax Transferred to Statement of Changes in Equity

399,677,667

456,551,799

521,519,120

595,731,291

680,503,853

777,339,552

(57,661,278) 11,051,489 (46,609,789)

(65,866,478) 12,624,116 (53,242,362)

(75,239,278) 14,420,528 (60,818,750)

(85,945,827) 16,472,569 (69,473,258)

(98,175,918) 18,816,615 (79,359,303)

(112,146,351) 21,494,220 (90,652,132)

353,067,878

403,309,437

460,700,370

526,258,033

601,144,551

686,687,420

17 Earnings Per Share (of TK. 10 /- each) 18 Number of shares used to compute EPS 19 Dividend 20 Provided Tax 21 Retain Earning

3.08 114,507,043

3.52 114,507,043

4.02 114,507,043

4.60 114,507,043

5.25 114,507,043

6.00 114,507,043

(156,145,966) (47,520,125) 149,401,787

(178,365,537) (54,282,239) 170,661,661

(203,746,953) (62,006,601) 194,946,816

(232,740,144) (70,830,141) 222,687,748

(265,859,067) (80,909,270) 254,376,214

(303,690,812) (92,422,659) 290,573,949

Pro Forma balance sheet

2007 2008 2009 2010 2011 2012 (Growth Rate = 14.23%)

Fixed Assets Current Assets Total Assets Non-Current Liabilities Current Liabilities Total Liabilities Share Premium Excess of Issue Price over Face Value of GDRs Capital Reserve on Merger Tax-Holiday Reserve

9,029,643,482 2,923,775,458 11,953,418,940 2,074,506,357 1,627,972,936 3,702,479,293 1,489,750,000 1,689,636,958 294,950,950 442,354,953

10,314,561,749 3,339,828,706 13,654,390,455 2,369,708,612 1,859,633,485 4,229,342,096 1,489,750,000 1,689,636,958 294,950,950 505,302,063

11,782,323,886 3,815,086,330 15,597,410,217 2,706,918,147 2,124,259,330 4,831,177,477 1,489,750,000 1,689,636,958 294,950,950 577,206,546

13,458,948,575 4,357,973,115 17,816,921,691 3,092,112,599 2,426,541,432 5,518,654,032 1,489,750,000 1,689,636,958 294,950,950 659,343,038

15,374,156,958 4,978,112,690 20,352,269,647 3,532,120,222 2,771,838,278 6,303,958,500 1,489,750,000 1,689,636,958 294,950,950 753,167,552

17,561,899,493 5,686,498,125 23,248,397,618 4,034,740,930 3,166,270,865 7,201,011,795 1,489,750,000 1,689,636,958 294,950,950 860,343,295

Retained Earning
Issued Share Capital Shareholders' Equity

3,189,176,356
1,145,070,430 8,250,939,647

3,642,996,151
1,308,013,952 8,930,650,074

4,161,394,504
1,494,144,338 9,707,083,296

4,753,560,942
1,706,761,077 10,594,002,964

5,429,992,664
1,949,633,178 11,607,131,302

6,202,680,620
2,227,065,979 12,764,427,802

Shareholders' Equity & Liabilities

11,953,418,940
0

13,159,992,171
(494,398,284)

14,538,260,772
(1,059,149,444)

16,112,656,996
(1,704,264,695)

17,911,089,802
(2,441,179,845)

19,965,439,597
(3,282,958,021)

Excess(Required) Fund

Market Shares
Bangladesh's largest Pharmaceutical Companies (by sales '08) Top 10 Square Incepta Sales in $ Mn $138.7 $ 52.1

Beximco
Acme Eskayef ACI Opsonin Renata Aristopharma Drug International

$ 49.0
$ 36.3 $ 32.1 $ 31.3 $ 29.7 $ 29.1 $ 28.8 $ 23.4

Company Shares

Sponsors

and Directors of BPL have 20.63%, Other financial and non financial Institutes have 11.25%, Foreign investors have 33.45% Public have 34.67% of shares of the company.

Company Specific News

On July 22, 2008 Beximco Pharmaceuticals Ltd. (BPL or the Company), the leading Bangladeshi pharmaceutical manufacturer and exporter, is pleased to announce that it has received approval (GMP Clearance) from Therapeutic Goods Administration (TGA), Australia for its new Oral Solid Dosage (Tablet, Capsule), and the Metered Dose Inhaler and Spray manufacturing facilities. BPL is the first Bangladeshi company to receive this regulatory approval from TGA, Australia through a stringent facility audit process. With an overall pharmaceutical market of around US 10 billion dollars, Australia is one of the richest pharmaceutical markets in the Asia-Pacific region and the 13th largest in the world. On 13 October, 2008 Beximco Pharmaceuticals Ltd. (BPL or the Company), the leading edge pharmaceutical manufacturer and the largest pharmaceutical exporter of Bangladesh has commenced exports to Chile, after receiving marketing authorization for a number of products from Instituto de Salud Publica de Chile (Drug Regulatory authority in Chile). With this, BPL has become the first Bangladeshi pharmaceutical company to obtain product registration in any Latin American country. On November 14, 2008 Beximco Pharmaceuticals Ltd. (BPL or the Company), the leading pharmaceutical manufacturer and the largest pharmaceutical exporter from Bangladesh, announces the achievement of a milestone today following the receipt of approval from the Ministry of Health of Gulf Cooperation Council (GCC) countries for BPL to commence export of medicines into the GCC. BPL is the first company from Bangladesh to receive this approval. On July 31, 2009 Beximco Pharmaceuticals Ltd. (BPL or the Company), the leading Bangladeshi pharmaceutical manufacturer and largest pharmaceutical exporter from Bangladesh, is pleased to announce that it has received GMP Certificate for its facility from National Health Surveillance Agency (Anvisa) of Brazil. BPL is the first Bangladeshi company to receive this regulatory approval from Anvisa through a stringent facility audit process

Recommendation

Quality Local

and Control

Market Share Sales Strategies

Dynamic Foreign Focus

Market

on Least Developed Countries (LDCs)